OncoPharm

The Landmarks of OncoPharm series returns to discuss 2 landmark studies (and 1 editorial) in head & neck cancer. Editorial: https://ascopubs.org/doi/pdf/10.1200/JCO.22.00274 EUORTC Study: https://www.nejm.org/doi/full/10.1056/NEJMoa032641 Intergroup Study: https://www.nejm.org/doi/full/10.1056/NEJMoa032646

Dive into the fascinating world of melanoma, exploring its different forms like cutaneous and uveal. Discover the significance of treatment strategies, including surgical resection and immune checkpoint inhibitors. Learn about melanoma's unique patterns of metastasis and the crucial role of the immune system. Don't forget the importance of regular screenings in early detection and management!

Treatment-free remission (TFR) rates in CML of close to 80% have recently been described (https://doi.org/10.1002/ajh.26550). The AGILE study. If you can't say anything nice. Checking back in on CHECKMATE 816 (neoadjuvant Nico-Chemo in NSCLC) and Keynote-177 (pembrolizumab in MSI-H/dMMR colorectal cancer).

Explore the hidden dangers of combining ribociclib with tamoxifen, particularly the risks of QT prolongation. Uncover insights from the MONALEESA-7 study that emphasize the importance of awareness for healthcare professionals. This cautionary tale sheds light on potential drug interactions and the crucial need for patient safety in cancer treatment.

Catching on recent FDA approvals on relatlimab/nivolumab (it's relatLimab not relatimab) as well as Lu-PSMA-177 based on the VISION trial.

Open up your Yelp app and check out Leukemia Pharmacist & Boston denizen Jessie Signorelli's recommendations for eating, drinking, & sight seeing in Boston. Also, great educational programming awaits!

Trastuzumab deruxtecan vs. trastuzumab trastuzumab

We look at two recent studies that illustrate a framework for how we identify risk factors and possible predictors of chemotherapy toxicity. Paclitaxel and skeletal muscle mass: https://doi.org/10.1111/bcp.15244 Sex differences of toxicity risk: https://doi.org/10.1200/jco.21.02377

Results from VESPER are now published, so we revisit neoadjuvant ddMVAC and its place as SOC in bladder cancer. Nivolumab nets a new approval with chemo for neoadjuvant treatment of NSCLC. A new CAR-T product is approved for multiple myeloma.

Delve into the fascinating origins of Acute Myelogenous Leukemia treatment with a look back at pivotal studies and key clinical trials. Discover the impactful evolution of the 7 plus 3 chemotherapy regimen that revolutionized AML therapy since the 1970s. The conversation also breezes through nostalgic references to 1975 films, weaving together a mix of historical insights and contemporary relevance in cancer treatment.